Drug Database
NO

norethindrone + ethinyl estradiol (low dose) (Femcon Fe / Femcon Fe / Ovcon 35 Fe)

✓ Approved

Warner Chilcott PLC · ESR1 · 小分子

什么是 norethindrone + ethinyl estradiol (low dose)?

norethindrone + ethinyl estradiol (low dose) 是一种小分子,由Warner Chilcott PLC研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Femcon Fe, Femcon Fe, Ovcon 35 Fe
公司Warner Chilcott PLC
药物类别小分子
分子靶点ESR1, PGR
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

norethindrone + ethinyl estradiol (low dose) 作用于 2 个分子靶点:

ESR1estrogen receptor 1 (ER, ESR)
PGRprogesterone receptor (NR3C3, PR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

相关研究文献

PubMedBMC medical imaging2026-11-18

Deep learning reconstruction combined with contrast enhancement boost improves image quality of low-contrast-dose ctpa: a prospective randomized study.

Xie Dingxiang D, Lin Jingyi J, Huang Mulan M, Lai Zhiman Z et al.

High-quality CT pulmonary angiography (CTPA) is vital for pulmonary embolism diagnosis. This study evaluated the effect of combining deep learning reconstruction (DLR) with contrast enhancement boost (CE-boost) in low-contrast-dose CTPA. In this prospective randomized trial (September-December 2023), 106 patients were assigned to a low-contrast-dose (3 mL/s, 30 mL; Group A) or standard-contrast-dose (4 mL/s, 50 mL; Group B) CTPA protocol. Four image datasets were generated from each case in Group A using a 2 × 2 factorial design: A1, hybrid iterative reconstruction (HIR); A2, DLR (AiCE); A3, HIR plus CE-boost; A4, DLR plus CE-boost. Group B used HIR. Quantitative (CT attenuation, noise, SNR, CNR) and qualitative (overall image quality, subsegmental artery visibility) endpoints were assessed with linear mixed models and ART ANOVA with Holm correction. Each group comprised 53 patients (mean age: 59 ± 15 vs. 58 ± 18 years; 27 vs. 26 women). DLR significantly reduced noise and improved SNR/CNR (all Holm-corrected p < 0.001). CE-boost significantly increased CT attenuation, SNR, and CNR (all p < 0.001) without affecting noise. A significant DLR × CE-boost interaction was observed for CNR in all ROIs (all p < 0.05), indicating synergy. Qualitatively, DLR improved both overall quality and visibility, whereas CE-boost improved visibility only. The combined protocol (A4) achieved the highest CNR and visibility among all four datasets, significantly surpassing both the baseline low-contrast-dose (A1) and standard-contrast-dose (Group B) protocols (all Bonferroni-corrected p < 0.0083/0.025). Combining DLR with CE-boost synergistically optimizes low-contrast-dose CTPA, enabling a 40% reduction in iodine load and a 25% reduction in injection rate while enhancing image quality beyond that of standard-contrast-dose imaging. This protocol may offer a viable strategy for patients requiring strict contrast limitation.

PMID 43046152
阅读全文 →
PubMedIranian journal of pharmaceutical research : IJPR2026-11-18

Adjunct Low-Dose Dexmedetomidine for Sedation in Mechanically Ventilated Children: An Exploratory Randomized Trial.

Farrokhian Amir A, Forouzan Najmeh N, Mirrahimi Bahador B, Hashemi Seyyedeh Masumeh SM et al.

Effective sedation in the pediatric intensive care unit (PICU) is complicated by the adverse effects of benzodiazepines and opioids. Dexmedetomidine may provide a benzodiazepine-sparing alternative with distinct pharmacologic properties. We hypothesized that adjunct, fixed low-dose, no-bolus dexmedetomidine would reduce midazolam and fentanyl exposure per ventilator-day in mechanically ventilated children. In a triple-blind randomized controlled trial, 60 mechanically ventilated patients aged 1 month to 12 years were randomized to standard sedation (continuous midazolam and fentanyl) plus low-dose dexmedetomidine (a fixed-rate continuous infusion at 0.2 µg/kg/h without a loading bolus) or matched placebo (0.9% normal saline). In both groups, midazolam and fentanyl were titrated per protocol to achieve the target Richmond Agitation-Sedation Scale (RASS) level. Among 60 randomized children, adjunct fixed low-dose dexmedetomidine did not reduce the prespecified primary outcome of fentanyl or midazolam exposure per ventilator-day. Median fentanyl exposure per ventilator-day was 70.0 µg·kg-1·day-1 in the control group and 90.6 µg·kg-1·day-1 in the dexmedetomidine group; median midazolam exposure per ventilator-day was 7.0 mg·kg-1·day-1 and 9.1 mg·kg-1·day-1, respectively. Neither primary comparison remained statistically significant after Holm correction. In an unadjusted secondary analysis, the median time to first successful extubation was 6 days in the dexmedetomidine group and 15 days in the control group. This finding was exploratory and was not confirmed by the prespecified competing-risk or longitudinal ventilation analyses. Adjunct fixed low-dose dexmedetomidine without a loading bolus did not reduce fentanyl or midazolam exposure per ventilator-day. Early sedative-analgesic exposure was higher with dexmedetomidine, and the apparent early-extubation signal was exploratory and was not confirmed by competing-risk or longitudinal analyses of ventilation.

PMID 43047987
阅读全文 →
PubMedFood science & nutrition2026-11-18

Effects of Walnut (Juglans regia L.) Consumption on Glycemic and Anthropometric Indices in Adults: A Systematic Review and Dose-Response Meta-Analysis.

Mashayekhi Ghazal G, Ashtary-Larky Damoon D, Karimi Mehdi M, Asbaghi Omid O et al.

Walnuts (Juglans regia L.) are nutrient-dense nuts rich in polyunsaturated fatty acids, fiber, and antioxidant phytochemicals that may influence glucose metabolism and body composition. This systematic review and dose-response meta-analysis aimed to quantitatively assess the effects of walnut consumption on glycemic indices and anthropometric parameters in adults. A literature search was conducted across PubMed, Scopus, and Web of Science through September 2026. Randomized controlled trials (RCTs) evaluating the effects of walnut supplementation compared with a placebo or control group on fasting blood sugar (FBS), fasting insulin (FI), hemoglobin A1c (HbA1c), HOMA-IR, body weight (BW), body mass index (BMI), and waist circumference (WC) were included. Weighted mean differences (WMDs) were pooled using random-effects models. Subgroup analyses, linear and non-linear dose-response models, and GRADE assessments were performed. Forty-eight RCTs (56 comparisons) were included. Overall, walnut consumption did not significantly affect FBS, FI, HbA1c, HOMA-IR, BW, BMI, or WC. Subgroup analyses showed significant reductions in BW among obese individuals and in low-dose (< 50 g/day) or crossover studies, while FBS increased slightly in participants with baseline FBS < 100 mg/dL. Non-linear analyses showed significant associations between walnut dose and changes in HbA1c, BW, and WC, and linear regression revealed a positive association between the duration of intervention and FI. According to the GRADE framework, the certainty of evidence was moderate for BW, low for FI and BMI, and very low for other outcomes. Walnut consumption was not associated with significant overall improvements in glycemic control or anthropometric parameters in adults. However, the findings should be interpreted cautiously given the overall low certainty of evidence and high risk of bias across the included studies. Although some subgroup analyses yielded statistically significant findings, these differences may not necessarily represent clinically meaningful effects. Further well-designed, low-risk-of-bias RCTs are warranted to clarify the potential effects of walnut consumption on glycemic and anthropometric outcomes.

PMID 43047961
阅读全文 →
PubMedJournal of aerosol medicine and pulmonary drug delivery2026-11-18

Inhalable IL-10 as an Aerosolized Therapeutic Approach to Acute Lung Injury in Mice.

Poole Jill A JA, Nelson Amy J AJ, Wyatt Todd A TA, Dudek Steven M SM et al.

Background:Acute lung injury (ALI) is a severe inflammatory condition with substantial morbidity and mortality, with no approved pharmacologic therapies targeting its underlying inflammatory pathways. Prior studies demonstrated that intratracheal interleukin (IL)-10 reduces lipopolysaccharide (LPS)- and organic dust-induced lung and systemic inflammation.Methods:The present study evaluated the aerosol performance and efficacy of nebulized IL-10 against a high-dose LPS-induced ALI model with comparisons to shock-dose dexamethasone (5 mg/kg, intraperitoneal injections). C57BL/6 male mice were challenged with LPS (5 mg/mL) and treated with low- (0.1 mg/mL), mid- (0.5 mg/mL), or high-dose (1 mg/mL) IL-10, or vehicle, all by nose-only aerosol inhalation (15-minute exposure duration), with euthanasia on day 2. Results:Aerosolized IL-10 exhibited a mass median aerodynamic diameter of 1.66 µm (geometric standard deviation 2.04). Pulmonary deposited doses were 5.5-5.7 µg/mouse for LPS and 10.4, 21.3, and 38.4 (ug/kg) for low-, mid-, and high-dose IL-10. LPS-induced weight loss (18.6%) was reduced by high IL-10 (8.4%) and dexamethasone (7.0%), with no significant difference between treatments. Increased lung weights (40.8%) following LPS challenge were significantly reduced by mid- and high-dose IL-10 and dexamethasone. LPS-induced airway total cell and neutrophil counts in bronchoalveolar lavage fluid were not reduced by either treatment. In contrast, IL-10 treatment produced dose-dependent reductions in LPS-induced pro-inflammatory mediators (TNF-α, IL-1β, IL-6, IL-12p70, IFN-γ, KC/CXCL1, MCP-1, and MIP-1α), with beneficial responses at the high IL-10 dose comparable to dexamethasone. Histopathology demonstrated dose-responsive reductions in LPS-induced peribronchovascular mixed cellular lung inflammation, significant at mid- and high IL-10 doses and comparable to dexamethasone.Conclusion:Overall, aerosolized IL-10 demonstrated aerodynamic properties consistent with deep lung penetration and dose-dependent efficacy at ≥21.3 µg/kg, achieving anti-inflammatory effects comparable with dexamethasone in this ALI murine model.

PMID 43046271
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

Low-Dose Oral Versus Topical Minoxidil in Androgenetic Alopecia: A Randomized, Double-Blind, Double-Dummy Controlled Trial.

Chaudhry Muhammad Asad Ejaz MAE, Muneeb Bushra B, Aamir Safoora S, Saeed Zoha Arif ZA et al.

Androgenetic alopecia (AGA) is a prevalent, progressive condition with significant psychosocial impact. Current pharmacological modalities like topical minoxidil and finasteride have limitations. Low-dose oral minoxidil has surfaced as a valid off-label solution, with the practical advantage of once-daily dosing. To evaluate the efficacy and safety of topical and oral minoxidil in AGA. In this double-blind, double-dummy randomized controlled trial, 100 patients aged 18-50 years with AGA were randomized to receive either twice-daily topical minoxidil (5% in males, 2% in females) plus a placebo tablet, or once-daily oral minoxidil (2.5 mg in males, 1.25 mg in females) plus a placebo spray for 6 months. The primary outcome was the proportion of patients achieving ≥ +1 improvement in a validated 7-point global photographic scale. Secondary outcomes included patient satisfaction and adverse effects. Data were analyzed using SPSS v26 with p ≤ 0.05 as significant. Ninety patients completed 24 weeks of follow-up. Photographic assessment demonstrated that mild-to-excellent improvement (≥ +1) occurred in both the oral (67%) and topical minoxidil (73%) groups (p = 0.652). Patient-reported satisfaction was high in both groups (topical: 70.5%; oral: 80.4%, p = 0.332), with a non-significant trend favoring oral minoxidil at the moderate satisfaction threshold (58.7% vs. 38.6%, p = 0.057). Median improvement scores were comparable between groups for both clinician assessment and patient-reported outcomes. Hypertrichosis was significantly more frequent with oral minoxidil (30% vs. 9%, p = 0.011), whereas contact dermatitis was exclusive to topical minoxidil (11% vs. 0%, p = 0.025). No serious adverse events were observed. Both topical and low-dose oral minoxidil demonstrated clinically meaningful improvement in androgenetic alopecia. Despite oral therapy exhibiting a trend toward higher patient satisfaction, this study was not powered to establish non-inferiority or equivalence. The dermatologist-assessed outcomes indicated no significant intergroup differences. Low-dose oral minoxidil may be considered a practical alternative in selected patients, particularly where adherence to topical therapy is limited. ClinicalTrials.gov: NCT07273799.

PMID 43047224
阅读全文 →
PubMedChina CDC weekly2026-11-18

Childhood Immunization Schedule for National Immunization Program Vaccines, China (Version 2026).

Administration National Disease Control And Prevention NDCAP, China National Health Commission Of The People's Republic Of NHCOTPRO

In June 2026, the National Disease Control and Prevention Administration and the National Health Commission issued the Childhood Immunization Schedule for National Immunization Program Vaccines (Version 2026). Compared with the 2021 version, the key updates include optimization of the five-dose Diphtheria-Tetanus-acellular Pertussis vaccine schedule (with the first dose advanced to 2 months of age and the fifth dose administered at 6 years of age); inclusion of the bivalent human papillomavirus vaccine in the National Immunization Program as a two-dose series for girls aged 13 years (Table 1); and expanded and refined vaccination guidance for children with medical conditions, including preterm and low-birthweight infants, children with allergies, children born to mothers living with human immunodeficiency virus, children with immune function abnormalities, jaundice, common congenital diseases, or common neurological diseases, and children receiving blood products. This English translation provides a reference for public health professionals.

PMID 43047791
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多norethindrone + ethinyl estradiol (low dose)